Augmentation by Bispecific F(ab')<sub><nobr>2</nobr></sub> Reactive with P-Glycoprotein and CD3 of Cytotoxicity of Human Effector Cells on P-Glycoprotein Positive Human Renal Cancer Cells期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

按检索

Augmentation by Bispecific F(ab')₂ Reactive with P-Glycoprotein and CD3 of Cytotoxicity of Human Effector Cells on P-Glycoprotein Positive Human Renal Cancer Cells

Authors:	Yuji Heike Ko Okumura Takashi Tsuruo

Institution:	The Third Department of Internal Medicine, The University of Tokushima, School of Medicine, 3-8-15 Kuramoto-cho, Tokushima 770;Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 1-37-1 Kami-Ikebukuro, Toshima-ku, Tokyo 170;Department of Immunology, School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113;institute of Applied Microbiology, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113

Abstract:	A bispecific F(ba')₂ was constructed that was composed of two Fab fragments, one derived from anti-CD3 monoclonal antibody (mAb) (OKT3) and the other from anti P-glycoprotein mAb (MRK 16). This bispecific F(ab')₂ enhanced the binding and cytotoxicity of human peripheral blood mononuclear cells (PBMCs) on P-glycoprotein-positive human kidney cancer cells (ADMHK/E). It had no effect on the cytotoxicity of PBMCs on P-glycoprotein-negative HK/E cells long-term cultured HK/E (LCHK/E)]. Control F(ab')₂ composed of OKT3 or MRK16 alone did not influence the cytotoxicity of PBMCs on ADMHK/E cells. These findings suggest that the MRK16-OKT3 bispecific F(ab')₂ may be therapeutically beneficial in treatment of human multidrug-resistant cancers.

Keywords:	Key words Multidrug resistance P-glycoprotein CD3 Bispecific F(ab')₂ Cytotoxicity

设为首页 | 免责声明 | 关于勤云 | 加入收藏